Lifestyle

Proposal to Approve MDMA for PTSD Treatment Fails

Jun 5 • 7 min read

A federal panel of independent health advisers convened yesterday to deliberate on a groundbreaking proposal to approve MDMA as a treatment for post-traumatic stress disorder (PTSD). Ultimately, Lykos’ proposal to approve MDMA for PTSD treatment was rejected with a decisive 1-10 vote, casting doubt on the possibility of federal approval later this summer. Examining the…

FSD Pharma Triumphs in Legal Dispute Against Former CEO Dr. Raza Bokhari

May 31 • 3 min read

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) has emerged victorious in its prolonged legal battle with the company’s former CEO, Dr. Raza Bokhari. Following years of litigation and an intensive eight-day evidentiary hearing, an arbitrator ruled against Bokhari, granting FSD Pharma three awards, including damages and compensation for the company’s arbitration-related fees and costs. On…

FTC’s Final Rule Amendment to the Health Breach Notification Rule and Its Implications

May 31 • 5 min read

On April 26, 2024, the Federal Trade Commission (FTC) issued a significant final rule amending its Health Breach Notification Rule (HBN Rule). This amendment aims to address the evolving landscape of personal health records (PHRs) and related technologies that fall outside the regulatory scope of the Health Insurance Portability and Accountability Act of 1996 (HIPAA)….

US FDA Staff Flags Concerns on MDMA-Assisted PTSD Treatment

May 31 • 2 min read

Earlier today, staff from the U.S. health regulatory body expressed concerns regarding the interpretation of data from trials on the psychedelic drug MDMA for treating post-traumatic stress disorder (PTSD). These concerns emerged ahead of an upcoming meeting of the agency’s advisory panel. The comments have set the stage for in-depth discussions on the benefits and…

Webinar: Analyzing the FDA Advisory Committee Review of MDMA-Assisted Therapy for PTSD

May 30 • 13 min read

Our expert panelists provide commentary on the June 4th FDA Committee meeting surrounding MDMA for PTSD, their interpretation of the meeting’s contents, and what it all means for MDMA therapy moving forward. “Analyzing the Lykos Therapeutics FDA Committee Meeting” was a live webinar event that streamed live across the Nucleus ecosystem on Wednesday, June 5th…

Pages: 12345678910111213141516171819202122